These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38104995)

  • 1. Cytokine Release Syndrome More than Two Years after Pembrolizumab Introduction.
    Nakashima K; Kitani K; Kono K; Yoshihara K; Kawakado K; Kobayashi M; Okuno T; Amano Y; Tsubata Y; Isobe T
    Intern Med; 2024 Aug; 63(15):2163-2166. PubMed ID: 38104995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy.
    Yoshimura A; Yamamoto Y; Nishikawa T; Fujita M; Inoue T; Kondo F; Hayashi T; Kawamura N; Nagahara A; Nakai Y; Nakayama M; Nishimura K
    Int Cancer Conf J; 2024 Jan; 13(1):26-32. PubMed ID: 38187183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report.
    Zhang M; Cheng Y; Hu Y; Nie L
    Thorac Cancer; 2022 May; 13(9):1419-1422. PubMed ID: 35384319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: A case report.
    Sekimata M; Kinjo Y; Tohyama A; Murakami M; Hashiwaki S; Saito Y; Higami S; Hagimoto M; Taketomi R; Hoshino K; Harada H; Ueda T; Kurita T; Matsuura Y; Yoshino K
    Oncol Lett; 2024 Jul; 28(1):331. PubMed ID: 38807673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.
    Murata D; Azuma K; Tokisawa S; Tokito T; Hoshino T
    Thorac Cancer; 2022 Oct; 13(20):2911-2914. PubMed ID: 36073307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine release syndrome induced by pembrolizumab: A case report.
    Zhang X; Fu Z; Yan C
    Medicine (Baltimore); 2022 Dec; 101(49):e31998. PubMed ID: 36626467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report.
    Gonugunta AS; von Itzstein MS; Gerber DE
    J Med Case Rep; 2022 Jul; 16(1):289. PubMed ID: 35871685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report.
    Sackstein P; Zaemes J; Kim C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysis.
    Ozaki T; Yumita S; Ogasawara S; Fujiya M; Tsuchiya T; Yoshino R; Sawada M; Akatsuka T; Izai R; Miwa C; Yonemoto T; Fujimoto K; Unozawa H; Fujiwara K; Kojima R; Kanzaki H; Koroki K; Inoue M; Kobayashi K; Nakamura M; Kiyono S; Kanogawa N; Kondo T; Nakagawa R; Nakamoto S; Kato N
    Hepatol Res; 2024 Jun; ():. PubMed ID: 38943555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic, programmed death-ligand 1-positive, non-small-cell lung cancer.
    Normand CV; Zender HO; Staehli DM; Chouiter-Djebaili AF; John G
    J Oncol Pharm Pract; 2021 Sep; 27(6):1528-1533. PubMed ID: 33353504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Thoracic Aortic Aneurysm in a Patient with Advanced Lung Adenocarcinoma Treated with Pembrolizumab.
    Ninomiya R; Kinehara Y; Tobita S; Konaka H; Jokoji R; Shintani T; Tachibana I
    Intern Med; 2022 Aug; 61(15):2339-2341. PubMed ID: 35022350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
    Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
    Awad MM; Gadgeel SM; Borghaei H; Patnaik A; Yang JC; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Altan M; Jalal SI; Panwalkar A; Gubens M; Sequist LV; Saraf S; Zhao B; Piperdi B; Langer CJ
    J Thorac Oncol; 2021 Jan; 16(1):162-168. PubMed ID: 33069888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatitis as immune-related adverse event during pembrolizumab therapy for multiple lung metastases from renal pelvic cancer.
    Kokura K; Watanabe J; Takuma T; Yokozeki H; Uketa S; Uemura Y
    IJU Case Rep; 2023 Nov; 6(6):402-405. PubMed ID: 37928307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.
    Kogure Y; Hashimoto H; Oki M
    Clin Lung Cancer; 2021 Nov; 22(6):e921-e924. PubMed ID: 34053861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
    Gadgeel SM; Stevenson JP; Langer CJ; Gandhi L; Borghaei H; Patnaik A; Villaruz LC; Gubens M; Hauke R; Yang JC; Sequist LV; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V
    Lung Cancer; 2018 Nov; 125():273-281. PubMed ID: 30429032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
    Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH
    Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
    Li D; He C; Xia Y; Du Y; Zhang J
    J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.